Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Dialysis-dependent ESKD
NCT05614115Phase 1Completed
- Sponsor
- University of Utah
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin in end-stage kidney disease (ESKD) (3 arms), sponsored by University of Utah. Primary endpoint: Study Completion at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT05614115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614115.